Your browser doesn't support javascript.
loading
Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction.
Lim, Shok Ping; Costantini, Benedetta; Mian, Syed A; Perez Abellan, Pilar; Gandhi, Shreyans; Martinez Llordella, Marc; Lozano, Juan Jose; Antunes Dos Reis, Rita; Povoleri, Giovanni A M; Mourikis, Thanos P; Abarrategi, Ander; Ariza-McNaughton, Linda; Heck, Susanne; Irish, Jonathan M; Lombardi, Giovanna; Marsh, Judith C W; Bonnet, Dominique; Kordasti, Shahram; Mufti, Ghulam J.
Afiliação
  • Lim SP; Department of Haematology, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
  • Costantini B; Department of Haematology, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
  • Mian SA; AOU Ospedali Riuniti Umberto I - Lancisi - Salesi, Clinica di Ematologia, Ancona, Italy.
  • Perez Abellan P; Department of Haematology, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
  • Gandhi S; Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Martinez Llordella M; Department of Haematology, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
  • Lozano JJ; Haematological Medicine, King's College Hospital, London, United Kingdom.
  • Antunes Dos Reis R; Haematological Medicine, King's College Hospital, London, United Kingdom.
  • Povoleri GAM; Centre for Inflammation Biology and Cancer Immunology, King's College London, London, United Kingdom.
  • Mourikis TP; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Bioinformatics Platform, Madrid, Spain.
  • Abarrategi A; Systems Cancer Immunology Laboratory, CRUK-KHP Cancer Centre, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
  • Ariza-McNaughton L; Centre for Inflammation Biology and Cancer Immunology, King's College London, London, United Kingdom.
  • Heck S; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Irish JM; Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Lombardi G; Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Marsh JCW; National Institute for Health Research Biomedical Research Centre, BRC Flow Core, Guy's and St Thomas Hospital, London, United Kingdom.
  • Bonnet D; Department of Cancer Biology, Vanderbilt University, Nashville, TN.
  • Kordasti S; MRC Centre for Transplantation, Peter Gorer Department of Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; and.
  • Mufti GJ; Department of Haematology, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Blood ; 136(7): 885-897, 2020 08 13.
Article em En | MEDLINE | ID: mdl-32294156
ABSTRACT
Idiopathic aplastic anemia (AA) has 2 key characteristics an autoimmune response against hematopoietic stem/progenitor cells and regulatory T-cells (Tregs) deficiency. We have previously demonstrated reduction in a specific subpopulation of Treg in AA, which predicts response to immunosuppression. The aims of the present study were to define mechanisms of Treg subpopulation imbalance and identify potential for therapeutic intervention. We have identified 2 mechanisms that lead to skewed Treg composition in AA first, FasL-mediated apoptosis on ligand interaction; and, second, relative interleukin-2 (IL-2) deprivation. We have shown that IL-2 augmentation can overcome these mechanisms. Interestingly, when high concentrations of IL-2 were used for in vitro Treg expansion cultures, AA Tregs were able to expand. The expanded populations expressed a high level of p-BCL-2, which makes them resistant to apoptosis. Using a xenograft mouse model, the function and stability of expanded AA Tregs were tested. We have shown that these Tregs were able to suppress the macroscopic clinical features and tissue manifestations of T-cell-mediated graft-versus-host disease. These Tregs maintained their suppressive properties as well as their phenotype in a highly inflammatory environment. Our findings provide an insight into the mechanisms of Treg reduction in AA. We have identified novel targets with potential for therapeutic interventions. Supplementation of ex vivo expansion cultures of Tregs with high concentrations of IL-2 or delivery of IL-2 directly to patients could improve clinical outcomes in addition to standard immunosuppressive therapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-2 / Apoptose / Linfócitos T Reguladores / Proteína Ligante Fas / Anemia Aplástica Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-2 / Apoptose / Linfócitos T Reguladores / Proteína Ligante Fas / Anemia Aplástica Idioma: En Ano de publicação: 2020 Tipo de documento: Article